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Abstract. Antimicrobials are used primarily to treat infectious disease, but they have other effects. Here, we assess
anthropometry measurements in children 6–60 months in 24 communities randomized to one or two mass azithromycin
distributions over a 1-year period in Niger. We compared the prevalence of wasting, low mid-upper arm circumference,
stunting, and underweight in communities in the two treatment arms. We were unable to prove that there was a
difference in the prevalence of wasting in the 12 communities that received one mass azithromycin distribution versus
the 12 communities that received two mass azithromycin distributions (odds ratio = 0.75, 95% confidence interval =
0.46–1.23). Likewise, we were unable to detect a difference in the two treatment arms for low mid-upper arm
circumference, stunting, and underweight. There may not be an association between antibiotic use and improved
growth in humans, or this trial was not powerful enough to detect an association if it exists.
INTRODUCTION
Antimicrobials are used primarily to treat infectious dis-
eases, although their effects are wide-ranging. A relationship
between malnutrition and infection has long been recognized.1
In young children in developing countries, a high proportion of
deaths from diarrhea, pneumonia, and malaria are attributable
to undernutrition.2 In fact, malnutrition is thought to play a
role in more than one-half of all childhood deaths worldwide
caused by these conditions.3 Periodic treatment or prevention
of these common childhood infections could theoretically
improve growth and lower mortality in children. If so, this
improvement would prove to be an important benefit of mass
azithromycin treatments for trachoma.
Azithromycin has some activity against infections that lead to
the three main causes of death in the developing world: pneu-
monia,4 diarrhea,5,6 and malaria.7 A case control8 and cluster-
randomized clinical trial9 showed that mass azithromycin
treatments were associated with reduced mortality in children.
However, if mass azithromycin treatments affect mortality, the
mechanism by which they do so is unknown. We aim to inves-
tigate explanatory factors for mortality reduction by measur-
ing anthropometric indices. Mass azithromycin treatments for
trachoma provide a unique opportunity to study the effect of
these treatments on growth and nutrition. The current investi-
gation is a substudy of the Partnership for the Rapid Elimina-
tion of Trachoma (PRET), a cluster-randomized clinical trial
(clinicaltrials.gov trial NCT00792922) investigating different
treatment strategies for trachoma, an ocular infection with
Chlamydia trachomatis. The study methods for PRET have
been previously described and are summarized briefly below.10
We hypothesize that children ages 6–60 months in 12 commu-
nities randomized to biannual mass azithromycin treatment
will have better growth and nutrition compared with children
in 12 communities randomized to annual mass azithromycin in
a substudy of a cluster-randomized clinical trial in Niger.
METHODS
Study setting and design. The study took place in the
Matameye district of the Zinder region of Niger. The district
is divided into grappes (government health units) that are
referred to as communities in this manuscript. Communities
were selected from six health centers (Center de Sante´ Inte´gre´e
[CSIs]). Inclusion criteria were total population between
250 and 600 persons and prevalence of active trachoma
(trachomatous inflammation - follicular [TF] and/or trachomatous
inflammation - intense [TI] using the World Health Organiza-
tion [WHO] system)11 ³ 10% in children ages 0–60 months.
There were 235 eligible communities in the six CSIs, of which
72 (31%) communities satisfied the inclusion criteria for size;
48 communities were randomly selected for the PRET study.
Community and individual randomization. The current
substudy took place in May of 2011 in 24 communities ran-
domized to two different mass antibiotic treatment strategies:
annual treatment of everyone or biannual treatment of chil-
dren 0–12 years. Eligible individuals > 6 months were offered
their assigned treatment of a single directly observed oral dose
of azithromycin (height-based dosing equaling 20 mg/kg) in
June or July of 2010. Children < 6 months were offered topical
tetracycline to be used two times daily for 6 weeks per the
WHO recommendation.12 A second mass antibiotic treatment
was offered to everyone in the biannually treated communities
in December of 2010 or January of 2011. All outcome mea-
surements were performed in a random sample of 50 children
ages 6–60 months in each of the 24 communities based on the
May of 2011 census. If the community did not contain 50 chil-
dren, all children were included. Randomization of communi-
ties to the treatment arms and randomization of individuals
within communities were done using RANDOM and SORT
functions in Excel (version 2003) or the statistical package R
(version 2.12; R Foundation for Statistical Computing, Vienna,
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Austria; www.r-project.org)13 by B.N. and T.C.P. as previously
described.14 Study teams monitored antibiotic treatment cover-
age levels in all communities at both treatments. Analyses were
performed at the community level on an intention-to-treat basis,
and no adjustments were made for missing or absent individuals.
Data collection and intervention and nutritional assessment.
Before the trial, field workers attended a 2-day workshop,
where the WHO training course on standard growth measure-
ment procedures15 was administered under the supervision of
study coordinators and researchers from the F. I. Proctor
Foundation, University of California at San Francisco. We mea-
sured recumbent length in children younger than 24 months or
standing height in children older than 24 months when the child
was able to stand to the nearest 0.1 cm (Shoreboard; Shorr
Productions, LLC, Olney, MD). We subtracted 0.7 cm from
the child’s length to derive an estimated height when a child
older than 24 months was too sick or weak to stand in accor-
dance with the WHO conversion formula.16 Children were
weighed standing when they were able at all ages or in the arms
of a parent or guardian when necessary without clothing or with
only light clothing to the nearest 0.1 kg (Seca 874 flat floor scale;
Seca GMBH & Co. Kg, Hamburg, Germany). Mid-upper arm
Figure 1. Participant flow.
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circumference (MUAC) was measured to the nearest 0.1 cm
using a non-stretchable tape developed by Johns Hopkins Uni-
versity.17 All anthropometry measurements were done in tripli-
cate by field workers trained to assess growth in infants and
children, and median values were used for analyses. Calibration
of height/length and weight measurements was done after every
10th person. Field workers referred severely ill or malnourished
children to local health posts for additional evaluation. Field
workers were not informed of treatment allocation or antibiotic
coverage at all visits. Community members were not masked to
their treatment assignment.
Statistical analysis. We calculated age- and sex-adjusted
community level nutritional z scores for wasting (weight-
for-height z score [WHZ]), low MUAC (MUAC z score
[MUACZ]), stunting (height-for-age z score [HAZ]), and
underweight (weight-for-age z score [WAZ]) using the WHO
Anthro software program16 based on the WHO child growth
standards.18 Low anthropometry was defined as < −2.0 z
scores of the median for the WHO reference population.19
We determined odds ratios for low anthropometry using mixed
effects logistic regression with community as a random effect.
We also assessed anthropometry measurements as continuous
outcomes using mixed effects linear regression with commu-
nity as a random effect. We calculated intraclass correlation
coefficients (ICCs) using similar models. As an exploratory
analysis, we compared community-level WHZ scores after
restricting inclusion to participants who took their assigned
treatment at baseline in all communities (mixed effects linear
regression with community as a random effect). To determine
if a dose–response relationship was present, we measured
WHZ scores that restricted inclusion to participants who took
their assigned treatment one time (baseline) or two times
(baseline and 6 months) in the biannually treated communities.
Finally, to confirm the presence of any dose response, we
measured WHZ scores that restricted inclusion to participants
who took their assigned treatment at baseline in the annually
treated communities.
Assuming 50 children per village, a = 0.05, ICC = 0.015
(from a clinical trial in Niger),20 and 8% prevalence of
wasting (from a clinical trial in Niger),20 inclusion of 12 state
teams per group would provide 80% power to detect an
absolute difference of 6%. We used the statistical package R
(version 2.12) or STATA 11 (Stata Corp., College Station,
TX) for all analyses.13
Human participants and consent procedures. Ethical
approval for this study was obtained from the Committee for
Human Research of the University of California, San
Francisco and le Comite´ Consultatif National d’Ethique du
Ministere de la Sante Publique, Niger (Ethical Committee,
Niger Ministry of Health). Oral consent was obtained from
the community leaders, and written (thumbprint) consent was
obtained from the child’s parent or guardian at the time of
examination. The study was carried out in accordance with
the Declaration of Helsinki.
RESULTS
A total of 48 communities were enrolled in PRET, with
12 communities randomized to annual treatment and 12 com-
munities randomized to biannual treatment according to the
study design (Figure 1). All communities received mass treat-
ment in June and July of 2010, and the biannually treated
communities received a second treatment in December of
2010 and January of 2011. There were 1,030 individuals
(6–60 months) in the 24 communities in this anthropometry
study (486 individuals in annually treated communities and
545 individuals in biannually treated communities). The mean
antibiotic coverage of children ages 6–60 months was 80.4%
(95% confidence interval [CI] = 76.8–84.1) for the single
treatment of the annually treated communities and 74.4%
(95% CI = 69.4–79.3) and 78.7% (95% CI = 74.6–82.7)
for the two treatments in the biannually treated commu-
nities. Anthropometry measurements were performed in
May of 2011, 10 or 11 months after treatment in the annual
arm and 6 months after treatment in the biannual arm as per
study design. Baseline characteristics, including average
number of children per community, age of children, fraction
female, and clinical trachoma prevalence, were similar in
the communities randomized to the two treatment arms
(Table 1). All communities received their scheduled treat-
ments, and no community was lost to follow-up over the
length of the study. There were no serious adverse events
attributed to the study medicine reported through a pas-
sive surveillance system throughout the entire length of
the study.
The odds of wasting were 25% less (odds ratio [OR] = 0.75,
95% CI = 54% less to 23% more), low MUAC was 7% less
(OR = 0.93, 95% CI = 41% less to 46% more), stunting was
11% less (OR = 0.89, 95% CI = 35% less to 22% more), and
underweight was 19% less (OR = 0.81, 95% CI = 43% less to
16% more) in the biannually treated communities than the
annually treated communities (mixed effects logistic regres-
sion with community as a random effect). The mean preva-
lence of severe wasting (WHZ < −3.0) was not different in
annually and biannually treated communities (OR = 1.08,
95% CI = 47% less to 222% more). The ICC was 0.019 (95%
CI = 0.000–0.043) for height and 0.022 (95% CI = 0.000–0.050)
for weight. In a linear model (mixed effects linear regression
with community as a random effect), we were unable to
detect a difference in anthropometry between the biannually
treated communities and the annually treated communities
(Tables 2 and 3).
With the analysis restricting enrollment to individuals who
participated in the program and received their assigned anti-
biotic treatment at baseline, there was no significant change in
the results for the association of antibiotic treatment and
anthropometry in the logistic regression models for wasting,
low MUAC, stunting, and underweight (data not shown).
However, WHZ was 50% higher in the biannually treated
Table 1
Baseline characteristics of 24 communities randomized (1:1) to
annual or biannual mass azithromycin treatment in a cluster-
randomized clinical trial for trachoma in Niger
Annual treatment
(12 communities)
Biannual treatment
(12 communities)
Children per community
< 60 months
124 (42–207) 118 (88–147)
Age of children (months) 30.8 (29.8–31.9) 31.9 (30.7–33.0)
Proportion female 51.3% (48.2–54.4) 50.1% (47.1–53.1)
Prevalence trachoma TF* 26.5% (14.9–38.0) 24.1% (15.9–32.3)
Prevalence trachoma TI* 8.6% (4.4–12.8) 9.4% (4.9–14.0)
All values are community-level means in children < 60 months with 95% CI values.
*Using the WHO simplified grading system.11
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communities than the annually treated communities in this
restricted analysis (mixed effects linear regression, 0.49, 95%
CI = 0.29–0.70, P < 0001). In the biannually treated communi-
ties, individuals who participated in the program and received
their assigned treatment at baseline had 35% higher WHZ
(0.35, 95% CI = −0.008 to 0.72, P = 0.056) than those individ-
uals who did not receive baseline treatment. Note that those
individuals who missed their baseline treatment but received
treatment at 6 months had a similar increase in their WHZ
score (0.34, 95% CI = −0.20 to 0.71), consistent with a dose
response for each antibiotic treatment. In these same com-
munities, individuals who received their assigned treatment
two times (at baseline and 6 months) had WHZ scores 65%
higher (0.65, 95% CI = 0.37–0.93, P < 0001) than those indi-
viduals who received no treatment.
DISCUSSION
This cluster-randomized clinical trial in Niger of children
ages 6–60 months shows that growth and nutrition are not
different in communities randomized to a single mass
azithromycin treatment versus communities randomized to
two mass azithromycin treatments. We were unable to detect
a difference in height, weight, and MUAC in the communities
that received a single additional mass treatment.
With the analysis restricting inclusion to participants who
received their prescribed antibiotics at baseline, we were
unable to show a difference in WHZ scores between commu-
nities randomized to annual treatment and communities ran-
domized to biannual treatment. Note that this restriction is a
deviation from our primary pre-specified intention-to-treat
analysis, where participants were not withdrawn after ran-
domization for any reason. We are aware that withdrawing
individuals from the study, even because of non-adherence,
may offer bias of unknown magnitude and direction.21 Never-
theless, these restricted analyses can present an estimate of
biological efficacy that intention-to-treat analyses may be
unable to provide.22 For example, we detected a dose response
in those individuals who received their assigned treatment, and
each additional treatment (from zero treatments to one treat-
ment and from one treatment to two treatments) resulted in a
WHZ score that was approximately 30% higher.
Although we did not detect a difference between annual
and biannual mass antibiotic treatments on anthropometry,
this finding may be because of the following reasons. First, a
single extra mass azithromycin treatment over the course of
1 year may not be sufficient to have an effect on growth. Second,
this study was a cross-sectional study and did not follow com-
munities longitudinally; a longitudinal study might be better able
to detect a smaller effect size. Third, there is a seasonal compo-
nent to wasting in Niger, with high prevalence from December
to February (after the rainy season) and lower prevalence in
October (in the dry season when our study took place).20 Per-
forming a study when wasting is at its lowest might make it
more difficult to detect an effect of mass antibiotic treatment.
The outcome measures were performed 1 year after treat-
ment in the annually treated communities and 6 months after
treatment in the biannually treated communities by study
design. In future studies, we plan to perform outcome mea-
surements at the same time after treatment in compared com-
munities to help with interpretation.
In conventional livestock production, antibiotics have been
used to enhance weight gain and promote growth since the
early 1950s.23 The use of antibiotics in food-producing animal
agriculture results in healthier, more productive animals,
lower disease incidence, and reduced morbidity and mortality,
although this practice is controversial.24 The biological basis
for the growth-promoting effects of oral antibiotics could be a
reduction in intestinal microflora, which compete for nutri-
ents,25 or treatment of subclinical infection.26,27 The Animal
Health Institute (AHI) estimates that between 9% and 17%
of all antibiotics sold in the United States for animals are for
growth promotion or improved feed efficiency.23 Antibiotics
are not currently prescribed for growth promotion in humans,
although treatment of children with deworming drugs has been
shown to increase weight in some studies.28 The mechanism
Table 2
Nutritional assessment of children ages 6–60 months in 24 communities randomized (1:1) to annual or biannual mass azithromycin treatment in a
cluster-randomized clinical trial
Measurement
Annual treatment (12 communities) Biannual treatment (12 communities)
OR (95% CI) P valuePercent Number/total Percent Number/total
Wasting 14.8 72/486 11.6 63/545 0.75 (0.46–1.23) 0.26
Low MUAC 20.2 98/486 18.5 101/545 0.93 (0.59–1.46) 0.74
Stunting 76.5 371/485 74.5 406/545 0.89 (0.65–1.22) 0.48
Underweight 64.1 311/485 59.5 324/545 0.81 (0.57–1.16) 0.26
ORs from mixed effects logistic regression use community as a random effect. All measurements are based on z score < −2.0. Numbers may be different because of some loss during
field examination.
Table 3
Nutritional z scores in children ages 6–60 months in 24 communities randomized (1:1) to annual or biannual mass azithromycin treatment in a
cluster-randomized clinical trial
Metric
Annual treatment (12 communities) Biannual treatment (12 communities)
Coefficient (95% CI)* P valueN Mean N Mean
WHZ 481 −0.89 ± 1.30 538 −0.78 ± 1.08 0.09 (−0.16 to 0.34) 0.48
MUACZ 483 −1.25 ± 1.01 541 −1.20 ± 0.93 0.03 (−0.18 to 0.23) 0.81
HAZ 482 −3.13 ± 2.24 541 −3.07 ± 1.71 0.07 (−0.31 to 0.45) 0.71
WAZ 483 −2.44 ± 1.45 541 −2.23 ± 1.24 0.12 (−0.15 to 0.39) 0.38
Numbers may be different because of some loss during field examination, and z scores could not be calculated for children age 5 years at the time of anthropometry.
*Mixed effects linear regression was used with community as a random effect; coefficient reflects the change in z score in the biannually treated arm relative to the annually treated arm.
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for the observed reduction in childhood mortality associated
with mass azithromycin treatments is unknown, and it may be,
in part, because of improved growth and nutrition.
Antibiotics do not provide a benefit for the treatment of
undernutrition based on our study. Mass azithromycin treat-
ments have proven to be very effective in programs for tra-
choma control, and the treatments are well-tolerated.29 Since
1999, over 225 million treatments of azithromycin have been
donated through the International Trachoma Initiative for
distribution by local partners in 19 countries.30 Investigation
of positive and negative secondary effects associated with
these treatments should be part of any mass treatment trial
or program, particularly study of emerging antibiotic resis-
tance. Although there is a large increase in the prevalence of
resistance in nasopharyngeal pneumococcus after mass anti-
biotic use,31 this resistance drops quickly when mass distri-
butions are discontinued.32 Nevertheless, a strategy that
provides antibiotics to large numbers of children to prevent
non-specific infectious diseases to improve growth parameters
is currently not advised based on our study.
In summary, we were unable to detect differences in
anthropometry measurements in communities randomized
to receive an extra mass azithromycin distribution; there
were fewer cases of stunting and wasting with the extra treat-
ment, but the result was not significant. There may not be an
association between antibiotics and enhanced growth, or this
trial may not have been powerful enough to detect an associ-
ation. Larger studies, longer studies, or longitudinal measure-
ments of growth may be able to find a beneficial effect of
antibiotics on growth if it exists.
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